Candel grants CCO 285K options at $10.03
Candel Therapeutics Chief Commercial Officer Mark E. Sims received a grant of stock options covering 285,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Candel Therapeutics Chief Commercial Officer Mark E. Sims received a grant of stock options covering 285,000 shares of common stock. The options have an exercise price of $10.03 per share and expire on July 6, 2036. Twenty-five percent vest on July 6, 2027, with the remainder vesting in 36 equal monthly installments, contingent on continued service.
Insider Trade Summary
Grant/Award: 285,000 shares
Grant/Award
1 txn
Insider
Sims Mark E.
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 285,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 285,000 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 285,000 contracts (Direct)
Footnotes (1)
- F1. 25% of the shares underlying this option shall vest and become exercisable on July 6, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options granted: 285,000 shares
Exercise price: $10.03 per share
Expiration date: July 6, 2036
+3 more
6 metrics
Options granted
285,000 shares
Stock option grant to Chief Commercial Officer
Exercise price
$10.03 per share
Stock option exercise price
Expiration date
July 6, 2036
Option term end
Initial vesting
25% on July 6, 2027
Cliff vesting date for portion of grant
Remaining vesting period
36 monthly installments
Post-cliff vesting schedule, subject to continued service
Total options after grant
285,000 shares
Total derivative holdings following transaction
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 10.0300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the shares underlying this option shall vest and become exercisable on July 6, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-07-06T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Candel Therapeutics (CADL) disclose about Mark E. Sims in this Form 4?
Candel Therapeutics reported that Chief Commercial Officer Mark E. Sims received a grant of stock options for 285,000 shares. These options give him the right to buy common stock at a fixed price, subject to a multi-year vesting schedule tied to continued service.
How many Candel Therapeutics (CADL) stock options were granted to Mark E. Sims?
Mark E. Sims was granted stock options on 285,000 shares of Candel Therapeutics common stock. This entire amount represents his option holdings following the reported transaction, according to the Form 4’s total shares following transaction disclosure.
What is the exercise price of Mark E. Sims’ Candel Therapeutics (CADL) stock options?
The stock options granted to Mark E. Sims have an exercise price of $10.03 per share. This means he can purchase Candel Therapeutics common stock at $10.03 once the options vest and before they expire in 2036, subject to plan terms.
When do Mark E. Sims’ Candel Therapeutics (CADL) options vest?
Twenty-five percent of the shares underlying the option vest on July 6, 2027. The remaining 75% then vest in thirty-six equal monthly installments, provided Mark E. Sims continues to serve the company on each scheduled vesting date.
When do the stock options granted to Mark E. Sims at Candel Therapeutics (CADL) expire?
The options granted to Mark E. Sims expire on July 6, 2036. He must exercise vested portions of the 285,000-share grant before that expiration date, subject to all conditions of the company’s equity compensation plan and his continued service.
Is Mark E. Sims’ Candel Therapeutics (CADL) option grant a market purchase or compensation award?
The Form 4 describes the transaction as a grant, award, or other acquisition. The exercise price is $10.03 per share and the options were granted at no cost, indicating this is a compensation-related stock option award rather than an open-market purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
